Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.37421/jmgm.2020.14.457 http://scihub22266oqcxt.onion/10.37421/jmgm.2020.14.457 32952595!7500620!32952595     free     free     free Warning: file_get_contents(https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&id=32952595&cmd=llinks): Failed to open stream: HTTP request failed! HTTP/1.1 429 Too Many Requests in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 215       J+Mol+Genet+Med 2020 ; 14 (3): ? Nephropedia Template TP {{tp|p=32952595|t=2020. Ramatroban as a Novel Immunotherapy for COVID-19 |pdf=|usr=}}{{32952595}} gab.com Text Ramatroban as a Novel Immunotherapy for COVID-19 JO: J Mol Genet Med http://www.kidney.de/pget.php?&tw=1&pmid=32952595 #FOAvip SARS-CoV-2 virus suppresses host innate and adaptive immune responses, thereby allowing the virus to proliferate, and cause multiorgan failure, especially in the elderly. Respiratory viruses stimulate cyclooxygenase-2 (COX-2) to generate prostanoids including Prostaglandin D(2) (PGD(2)) and thromboxane A(2). Furthermore, PGD(2) concentrations in the airways increase with aging. PGD(2) action mediated via DP(2) receptors suppresses both innate and adaptive immune responses, by inhibiting interferon-lambda and stimulation of myeloid monocyte-derived suppressor cells respectively. PGD(2) and thromboxane A(2) actions via the TP receptors activate platelets leading to a prothrombotic state. Ramatroban, a small-molecule antagonist of DP(2) and TP receptors, reverses viremia-associated proinflammatory, immunosuppressive5 and prothrombotic processes which are similar to those induced by SARS-Cov-2. Ramatroban, used for the treatment of allergic rhinitis in Japan for the past 20 years has an excellent safety profile. Therefore, Ramatroban merits investigation as a novel immunotherapy for the treatment of COVID-19 disease. Twit Text FOAVip Ramatroban as a Novel Immunotherapy for COVID-19 ????J Mol Genet Med http://www.kidney.de/pget.php?&tw=1&pmid=32952595 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32952595 #FOAvip English Wikipedia <ref>{{Cite pmid|32952595}}</ref> Ramatroban as a Novel Immunotherapy for COVID-19 #MMPMID32952595 Gupta A; Kalantar-Zadeh K; Reddy ST J Mol Genet Med 2020[]; 14 (3): ? PMID32952595show ga SARS-CoV-2 virus suppresses host innate and adaptive immune responses, thereby allowing the virus to proliferate, and cause multiorgan failure, especially in the elderly. Respiratory viruses stimulate cyclooxygenase-2 (COX-2) to generate prostanoids including Prostaglandin D(2) (PGD(2)) and thromboxane A(2). Furthermore, PGD(2) concentrations in the airways increase with aging. PGD(2) action mediated via DP(2) receptors suppresses both innate and adaptive immune responses, by inhibiting interferon-lambda and stimulation of myeloid monocyte-derived suppressor cells respectively. PGD(2) and thromboxane A(2) actions via the TP receptors activate platelets leading to a prothrombotic state. Ramatroban, a small-molecule antagonist of DP(2) and TP receptors, reverses viremia-associated proinflammatory, immunosuppressive5 and prothrombotic processes which are similar to those induced by SARS-Cov-2. Ramatroban, used for the treatment of allergic rhinitis in Japan for the past 20 years has an excellent safety profile. Therefore, Ramatroban merits investigation as a novel immunotherapy for the treatment of COVID-19 disease. ?Ramatroban as a Novel Immunotherapy for COVID-19 (epmc).pdf DeepDyve Pubget Overpricing